Reuters - Girls aged 10 to 14 who received
GlaxoSmithKline Plc's vaccine to prevent infection with
the virus that causes cervical cancer had immune responses
twice as strong as women 15-25 years old given the vaccine, the
company said on Saturday, describing results of a late-stage
trial.
View the entire article:
Cancer vaccine has strong response in young girls (Reuters)